International Journal of Radiation Oncology * Biology * Physics
Volume 77, Issue 5 , Pages 1345-1351 , 1 August 2010

Nonresected Non–Small-Cell Lung Cancer in Stages I Through IIIB: Accelerated, Twice-Daily, High-Dose Radiotherapy—A Prospective Phase I/II Trial With Long-Term Follow-Up

  • Karl Wurstbauer, M.D.

      Affiliations

    • Department of Radiation Oncology, Paracelsus Medical University, Salzburg, Austria
    • radART–Institute for Research and Development on Advanced Radiation Technologies, Paracelsus Medical University, Salzburg, Austria
    • Corresponding Author InformationReprint requests to: Karl Wurstbauer, M.D., Universitätsklinik für Radiotherapie, Müllner Hauptstrasse 48, A-5020 Salzburg, Austria. Tel: (+43) 662-4482-3900; Fax: (+43) 662-4482-3903
    • ,
  • Heinz Deutschmann, M.Sc.

      Affiliations

    • Department of Radiation Oncology, Paracelsus Medical University, Salzburg, Austria
    • radART–Institute for Research and Development on Advanced Radiation Technologies, Paracelsus Medical University, Salzburg, Austria
    • ,
  • Peter Kopp, Ph.D.

      Affiliations

    • Department of Radiation Oncology, Paracelsus Medical University, Salzburg, Austria
    • radART–Institute for Research and Development on Advanced Radiation Technologies, Paracelsus Medical University, Salzburg, Austria
    • ,
  • Manfred Kranzinger, M.D.

      Affiliations

    • Department of Radiation Oncology, Paracelsus Medical University, Salzburg, Austria
    • radART–Institute for Research and Development on Advanced Radiation Technologies, Paracelsus Medical University, Salzburg, Austria
    • ,
  • Florian Merz, Ph.D.

      Affiliations

    • Department of Radiation Oncology, Paracelsus Medical University, Salzburg, Austria
    • radART–Institute for Research and Development on Advanced Radiation Technologies, Paracelsus Medical University, Salzburg, Austria
    • ,
  • Olaf Nairz, Ph.D.

      Affiliations

    • Department of Radiation Oncology, Paracelsus Medical University, Salzburg, Austria
    • radART–Institute for Research and Development on Advanced Radiation Technologies, Paracelsus Medical University, Salzburg, Austria
    • ,
  • Michael Studnicka, M.D.

      Affiliations

    • Department of Pneumology, Paracelsus Medical University, Salzburg, Austria
    • ,
  • Felix Sedlmayer, M.D.

      Affiliations

    • Department of Radiation Oncology, Paracelsus Medical University, Salzburg, Austria
    • radART–Institute for Research and Development on Advanced Radiation Technologies, Paracelsus Medical University, Salzburg, Austria

Received 16 February 2009 ,Revised 24 June 2009 ,Accepted 24 June 2009.

References 

  1. Youlden D, Cramb S, Baade P. The international epidemiology of lung cancer. Geographical distribution and secular trends. J Thorac Oncol. 2008;3:819–831
  2. Curran WJ, Scott C, Langer C, et al. Long-term benefit is observed in a phase III comparison of sequential versus concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer: RTOG 9410 [Abstract 2499]. Proc Am Soc Clin Oncol. 2003;22:621
  3. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiation therapy in combination with mitomycin, vindesine, and cisplatin in unresectable Stage III non-small cell lung cancer. J Clin Oncol. 1999;17:2692–2699
  4. Sause WT, Kolesar P, Taylor S, et al. Final results of a phase III trial in regionally advanced unresectable non-small cell lung cancer. Chest. 2000;117:358–364
  5. Kong FM, Ten Haken RK, Schipper MJ, et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small cell lung cancer: Long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys. 2005;63:324–333
  6. Cox JD, Pajak T, Asbell S, et al. Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell lung cancer of the lung: Analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials. Int J Radiat Oncol Biol Phys. 1993;27:493–498
  7. Machtay M, Hsu C, Komaki R, et al. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small cell lung carcinoma: Analysis of the Radiation Therapy Oncology Group (RTOG) experience. Int J Radiat Oncol Biol Phys. 2005;63:667–671
  8. Fowler J. Biological factors influencing optimum fractionation in radiation therapy. Acta Oncol. 2001;40:712–717
  9. Wurstbauer K, Deutschmann H, Kranzinger M, et al. Radiotherapy for lung cancer: Target splitting by asymmetric collimation enables reduction of radiation doses to normal tissues and dose escalation. Int J Radiat Oncol Biol Phys. 1999;44:333–341
  10. Wurstbauer K, Deutschmann H, Kopp P, et al. Target splitting in radiation therapy for lung cancer: Further developments and exemplary treatment plans. Radiat Oncol. 2009;4:30
  11. Wurstbauer K, Deutschmann H, Kopp P, et al. NSCLC in advanced stages: Radiotherapy by target-splitting with doses >80Gy—Low toxicity, encouraging survival [Abstract]. Lung Cancer. 2003;41(Suppl. 2):136
  12. I.C.R.U. report 62. Prescribing, recording and reporting photon beam therapy (supplement to ICRU report 50). Bethesda, MD: International Commission on Radiation Units & Measurements; 1999;
  13. Wurstbauer K, Deutschmann H, Kopp P, Sedlmayer F. Radiotherapy planning for lung cancer: Slow CTs allow the drawing of tighter margins. Radiother Oncol. 2005;75:165–170
  14. Wurstbauer K, Merz F, Sedlmayer F. Prophylactic administration of Amphotericine B to prevent esophagitis in thoracic radiotherapy—A prospective study. Strahlenther Onkol. 2009;185:512–516
  15. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–1346
  16. Giraud P, Antoine M, Larrouy A, et al. Evaluation of microscopic tumor extension in non-small cell lung cancer for three-dimensional conformal radiotherapy planning. Int J Radiat Oncol Biol Phys. 2000;48:1015–1024
  17. Rosenzweig KE, Fox JL, Yorke E, et al. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung carcinoma. Cancer. 2005;103:2118–2127
  18. Rosenman J, Halle J, Socinski M, et al. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small cell lung cancer: Technical issues and results of a phase I/II trial. Int J Radiat Oncol Biol Phys. 2002;54:348–356
  19. Bradley J, Graham M, Winter K, et al. Toxicity and outcome results of RTOG 9311: A phase I-II dose escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys. 2005;61:318–328
  20. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in Stage III non-small ling cancer. N Engl J Med. 1990;323:940–945
  21. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 1992;326:524–530
  22. Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small cell lung cancer: Groupe Lyon-Saint Etienne d'Oncologie Thoracique–Groupe Francais de Pneumo-Cancérologie NPC 95-01 study. J Clin Oncol. 2005;23:5910–5917
  23. El Sharouni SY, Kal HB, Battermann JJ. Accelerated regrowth of non-small cell lung tumours after induction chemotherapy. Br J Cancer. 2003;89:2184–2189
  24. Davis A, Tannock I. Repopulation of tumour cells between cycles of chemotherapy: A neglected factor. Lancet Oncol. 2000;1:86–93
  25. Belderbos J, Heemsbergen W, De Jaeger K, Baas P, Lebesque J. Final results of a phase I/II dose escalation trial in non-small lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66:126–134
  26. Saunders MI, Dische S, Barrett A, et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: Mature data from the randomised multicenter trial. Radiother Oncol. 1999;52:137–148
  27. King SC, Acker JC, Kussin PS, et al. High-dose, hyperfractionated, accelerated radiotherapy using a concurrent boost for the treatment of nonsmall cell lung cancer: Unusual toxicity and promising early results. Int J Radiat Oncol Biol Phys. 1996;36:593–599
  28. Maguire P, Marks L, Sibley G, et al. 73,6 Gy and beyond: Hyperfractionated, accelerated radiotherapy for non-small cell lung cancer. J Clin Oncol. 2001;19:705–711
  29. Nyman J, Bergman B, Mercke C. Accelerated hyperfractionated radiotherapy combined with induction and concomitant chemotherapy for inoperable non-small lung cancer. Acta Oncol. 1998;37:539–545
  30. De Ruysscher D, Wanders R, van Haren E, et al. Hi-Chart: A phase I/II study on the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2008;71:132–138
  31. Rosenzweig K, Sura S, Jackson A, Yorke E. Involved-field radiation therapy for inoperable non-small cell lung cancer. J Clin Oncol. 2007;25:5557–5561
  32. Armstrong J, Raben A, Zelefsky M, et al. Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer. Radiother Oncol. 1997;44:17–22
  33. Graham M, Purdy J, Emami B, Matthews J, Harms W. Preliminary results of a prospective trial using three-dimensional radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys. 1995;33:993–1000
  34. Leibel SA, Armstrong JG, Kutcher GL, et al. 3-D conformal radiation therapy for non-small lung carcinoma. In:  Meyer JL,  Purdy JA editor. 3-D conformal radiotherapy. Vol 29. Basel: Karger; 1996;p. 199–206
  35. Mayo C, Urie M, Fitzgerald T, et al. Hybrid IMRT for treatment of cancer of the lung and esophagus. Int J Radiat Oncol Biol Phys. 2008;71:1408–1418
  36. Wurstbauer K, Deutschmann H, Kopp P, et al. NSCLC: Primary tumor size—Radiation dose–related accelerated, twice daily radiotherapy by target splitting, preceded by two cycles of chemotherapy—First results of a prospective study. Strahlenther Onkol. 2007;183(Suppl. 2):36–38
  37. Wurstbauer K, Deutschmann H, Kopp P, et al. NSCLC: Primary tumor size—Radiation dose–related accelerated, twice daily radiotherapy by target splitting [Abstract]. Radiother Oncol. 2008;88(Suppl. 2):88

 Conflict of interest: none.

PII: S0360-3016(09)01016-5

doi: 10.1016/j.ijrobp.2009.06.060

International Journal of Radiation Oncology * Biology * Physics
Volume 77, Issue 5 , Pages 1345-1351 , 1 August 2010

Article Tools